UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30, 2022~~March 31, 2023

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to ______

Commission File Number: 001-36612

ReWalk Robotics Ltd.

(Exact name of registrant as specified in charter)

Israel	Not applicable
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

3 Hatnufa Street, Floor 6, Yokneam Ilit, Israel	2069203
(Address of principal executive offices)	(Zip Code)
+972.4.959.0123 Registrant's telephone number, including area code Not Applicable (Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act		~~(Zip Code)~~

~~+972.4.959.0123~~

~~Registrant’s telephone number, including area code~~

~~Not Applicable~~

~~(Former name, former address and former fiscal year, if changed since last report)~~

~~Securities registered pursuant to Section 12(b) of the Act:~~

Title of each class		Trading ~~symbol~~ Symbol		Name of each exchange on which registered
Ordinary shares, par value NIS 0.25		RWLK		Nasdaq Capital Market

Indicate by a check mark whether the ~~Registrant~~registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated ~~filer”,~~filer,” “accelerated ~~filer”,~~filer,” “smaller reporting ~~company”~~company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

~~Yes ☐No ☒~~

As of ~~August, 9, 2022,~~May 11, 2023, the ~~Registrant~~registrant had outstanding ~~62,823,243~~ 59,570,788 ordinary shares, par value NIS 0.25 per share.

REWALK ROBOTICS LTD.

FORM 10-Q

FOR THE QUARTER ENDED ~~JUNE 30, 2022~~MARCH 31, 2023

TABLE OF CONTENTS

		Page No.
GENERAL AND WHERE YOU CAN FIND MORE INFORMATION		2ii
PART I	FINANCIAL INFORMATION	31
ITEM 1.	FINANCIAL STATEMENTS (unaudited)	1
	CONDENSED CONSOLIDATED BALANCE SHEETS - MARCH 31, 2023 AND DECEMBER 31, 2022	1
	CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - THREE MONTHS ENDED MARCH 31, 2023 AND 2022	3
	CONDENSED ~~CONSOLIDATED BALANCE SHEETS~~STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - ~~JUNE 30,~~MARCH 31, 2023 AND 2022 ~~AND DECEMBER 31, 2021~~	~~3-4~~4
	CONDENSED CONSOLIDATED STATEMENTS OF ~~OPERATIONS~~CASH FLOWS - THREE ~~AND SIX~~ MONTHS ENDED ~~JUNE 30,~~MARCH 31, 2023 AND 2022 ~~AND 2021~~	5
	~~CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY - JUNE 30, 2022 AND 2021~~	~~6-7~~
	~~CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - SIX MONTHS ENDED JUNE 30, 2022 AND 2021~~	8
	NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	~~9-26~~6
ITEM 2.	~~MANAGEMENT’S~~MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	2723
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	3733
ITEM 4.	CONTROLS AND PROCEDURES	3733
PART II	OTHER INFORMATION	3834
ITEM 1.	LEGAL PROCEEDINGS	3834
ITEM 1A.	RISK FACTORS	3834
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	38 35
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	38 35
ITEM 4.	MINE SAFETY DISCLOSURES	38 35
ITEM 5.	OTHER INFORMATION	38 35
ITEM 6.	EXHIBITS	39 36
SIGNATURES		4037

Introduction and Where You Can Find Other Information

As used in this quarterly report on Form 10-Q (this “quarterly report”), the terms “ReWalk,” the “Company,” “RRL,” “we,” “us” and “our” refer to ReWalk Robotics Ltd. and its subsidiaries, unless the context clearly indicates otherwise. Our website is www.rewalk.com. Information contained in, or that can be accessed through, our website does not constitute a part of this quarterly report ~~on Form 10-Q~~ and is not incorporated by reference herein. We have included our website address in this quarterly report solely for informational purposes. Information that we furnish to or file with the Securities and Exchange Commission (the “SEC”), including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to, or exhibits included in, these reports are available for download, free of charge, on our website as soon as reasonably practicable after such materials are filed with or furnished to the SEC. Our SEC filings, including exhibits filed or furnished therewith, are also available on the SEC’s website at http://www.sec.gov.

Special Note Regarding Forward-Looking Statements

In addition to historical information, this quarterly report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies, financing plans, competitive position, industry environment, potential growth opportunities, potential market opportunities and the effects of competition. Forward-looking statements may include projections regarding our future performance and, in some cases, can be identified by words like “anticipate,” “assume,” “believe,” “could,” “seek,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “should,” “will,” “would” or similar expressions that convey uncertainty of future events or outcomes and the negatives of those terms. These statements may be found in ~~this~~the section of this quarterly report titled “Part I, Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this quarterly report. These statements include, but are not limited to, statements regarding:

•	our expectations regarding future growth, including our ability to increase sales in our existing geographic markets and expand to new markets;
•	our ability to maintain and grow our reputation and the market acceptance of our products;
•	our ability to achieve reimbursement from third-party payors or advance Centers for Medicare & Medicaid Services (“CMS”) coverage for our ~~products;~~products, including our ability to successfully submit cases for Medicare coverage through Medicare Administrative Contractors;
•	our ability to regain and maintain compliance with the continued requirements of the Nasdaq Capital Market and the risk that our ordinary shares will be delisted if we do not comply with such requirements;
•	the adverse effect that the COVID-19 pandemic has had and continues to have on our business and results of operations;
•	our ability to have sufficient funds to meet certain future capital requirements, which could impair our efforts to develop and commercialize existing and new products;
•	our limited operating history and our ability to leverage our sales, marketing and training infrastructure;
•	our ability to grow our business through acquisitions of businesses, products or technologies, and the failure to manage acquisitions, or the failure to integrate them with our existing business, which could have a material adverse effect on our business, financial condition, and operating results;
•	our expectations as to our clinical research program and clinical results;
•	our ability to obtain certain components of our products from third-party suppliers and our continued access to our product manufacturers;
•	our ability to improve our products and develop new products;
•	our compliance with medical device reporting regulations to report adverse events involving our products, which could result in voluntary corrective actions or enforcement actions such as mandatory recalls, and the potential impact of such adverse events on our ability to market and sell our products;
•	our ability to gain and maintain regulatory approvals and to comply with any post-marketing requests
•	~~the risk of a cybersecurity attack or breach of our information technology systems significantly disrupting our business operations;~~
•		our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;

•	the impact of substantial sales of our shares by certain shareholders on the market price of our ordinary shares;
•	our ability to use effectively the proceeds of our offerings of securities;
•	the ~~risk of substantial dilution resulting from the periodic issuances of our ordinary shares;~~
•		~~the~~ impact of the market price of our ordinary shares on the determination of whether we are a passive foreign investment company;
•	market and other ~~conditions;~~conditions, including the extent to which inflation or global instability may disrupt our business operations or our financial condition or the financial condition of our customers and suppliers; and
•	other factors discussed in the “Risk Factors” section of our ~~2021~~2022 annual report on Form 10-K and in our subsequent reports filed with the SEC.

The preceding list is not intended to be an exhaustive list of all of our forward-looking statements. The statements are based on our beliefs, assumptions, and expectations of future performance, taking into account the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance, or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the statements. In particular, you should consider the risks provided under “Part I, Item 1A. Risk Factors” of our ~~2021~~2022 annual report on Form 10-K, and in other reports subsequently filed by us with, or furnished to, the SEC.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur.

Any forward-looking statement in this quarterly report speaks only as of the date hereof. Except as required by law, we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future developments or otherwise.

2iii

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

REWALK ROBOTICS LTD. AND SUBSIDIARIES

~~CONDENSED CONSOLIDATED BALANCE SHEETS~~

~~(In thousands, except share and per share data)~~

June 30,

December 31,

2022

2021

(unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$
78,832

$
88,337

Trade receivable, net

866

585

Prepaid expenses and other current assets

957

610

Inventories

3,098

2,989

Total current assets

83,753

92,521

LONG-TERM ASSETS

Restricted cash and other long-term assets

1,020

1,064

Operating lease right-of-use assets

744

881

Property and equipment, net

281

284

Total long-term assets

2,045

2,229

Total assets

$
85,798

$
94,750

~~The accompanying notes are an integral part of these condensed consolidated financial statements.~~

~~REWALK ROBOTICS LTD. AND SUBSIDIARIES~~

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

June 30,

December 31,

2022

2021

(unaudited)

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES

Current maturities of operating leases

$
610

$
641

Trade payables

1,552

1,384

Employees and payroll accruals

965

1,142

Deferred revenues

335

316

Other current liabilities

337

555

Total current liabilities

3,799

4,038

LONG-TERM LIABILITIES

Deferred revenues

810

866

Non-current operating leases

207

418

Other long-term liabilities

69

45

Total long-term liabilities

1,086

1,329

Total liabilities

4,885

5,367

COMMITMENTS AND CONTINGENT LIABILITIES

SHAREHOLDERS’ EQUITY

Share capital

Ordinary share of NIS 0.25 par value-Authorized: 120,000,000 shares at June 30, 2022 and December 31, 2021; Issued and outstanding: 62,678,308 and 62,480,163 shares at June 30, 2022 and December 31, 2021, respectively

4,675

4,661

Additional paid-in capital

279,215

278,903

Accumulated deficit

(202,977
)

(194,181
)
Total shareholders’ equity

80,913

89,383

Total liabilities and shareholders’ equity

$
85,798

$
94,750

	March 31,		December 31,
	2023		2022
	(unaudited)
ASSETS

CURRENT ASSETS

Cash and cash equivalents	$	61,883	$	67,896
Trade receivable, net		532		1,036
Prepaid expenses and other current assets		1,434		649
Inventories		3,027		2,929
Total current assets		66,876		72,510

LONG-TERM ASSETS

Restricted cash and other long-term assets		692		694
Operating lease right-of-use assets		1,250		836
Property and equipment, net		160		196
Total long-term assets		2,102		1,726
Total assets	$	68,978	$	74,236

The accompanying notes are an integral part of these condensed consolidated financial statements.

REWALK ROBOTICS LTD. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
BALANCE SHEETS

(In thousands, except share and per share data)

Three Months Ended
June 30,

Six Months Ended
June 30,

2022

2021

2022

2021

Revenues

$
1,570

$
1,436

$
2,446

$
2,752

Cost of revenues

824

709

1,435

1,318

Gross profit

746

727

1,011

1,434

Operating expenses:

Research and development, net

956

810

1,863

1,605

Sales and marketing

2,347

1,613

4,531

3,284

General and administrative

1,819

1,445

3,281

2,707

Total operating expenses

5,122

3,868

9,675

7,596

Operating loss

(4,376
)

(3,141
)

(8,664
)

(6,162
)
Financial expenses (income), net

44

(9
)

68

(13
)

Loss before income taxes

(4,420
)

(3,132
)

(8,732
)

(6,149
)
Taxes on income

26

9

64

54

Net loss

$
(4,446
)

$
(3,141
)

$
(8,796
)

$
(6,203
)

Net loss per ordinary share, basic and diluted

$
(0.07
)

$
(0.07
)

$
(0.14
)

$
(0.15
)

Weighted average number of shares used in computing net loss per ordinary share, basic and diluted

62,544,467

46,123,222

62,519,063

41,210,527

	March 31,			December 31,
	2023			2022
	(unaudited)
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Current maturities of operating leases liability	$	624		$	564
Trade payables		1,781			1,950
Employees and payroll accruals		513			1,282
Deferred revenues		357			301
Other current liabilities		608			685
Total current liabilities		3,883			4,782

LONG-TERM LIABILITIES
Deferred revenues		895			890
Non-current operating leases liability		657			333
Other long-term liabilities		24			66
Total long-term liabilities		1,576			1,289

Total liabilities		5,459			6,071

COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders’ equity:

Share capital
Ordinary share of NIS 0.25 par value-Authorized: 120,000,000 shares at March 31, 2023 and December 31, 2022; Issued: 63,145,562 and 63,023,506 shares at March 31, 2023 and December 31, 2022, respectively; Outstanding: 59,482,004 and 60,090,298 shares as of March 31, 2023 and December 31, 2022 respectively		4,445			4,489
Additional paid-in capital		280,152			279,857
Treasury Shares at cost, 3,663,558 and 2,933,208 ordinary shares at March 31, 2023 and December 31, 2022 respectively		(3,007	)		(2,431	)
Accumulated deficit		(218,071	)		(213,750	)
Total shareholders’ equity		63,519			68,165
Total liabilities and shareholders’ equity	$	68,978		$	74,236

The accompanying notes are an integral part of these condensed consolidated financial statements.

REWALK ROBOTICS LTD. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF ~~CHANGES IN SHAREHOLDERS’ EQUITY~~
OPERATIONS

(Unaudited)

(In thousands, except share and per share data)

Ordinary Shares

Additional
paid-in

Accumulated

Total
shareholders’

Number

Amount

capital

deficit

equity

Balance as of April 1, 2021

46,092,577

3,385

250,141

(184,507
)

69,019

Share-based compensation to employees and non-employees

-

-

200

-

200

Issuance of ordinary shares upon vesting of RSUs by employees and non-employees

108,475

9

(9
)

-

-

Net loss

-

-

-

(3,141
)

(3,141
)
Balance as of June 30, 2021

46,201,052

3,394

250,332

(187,648
)

66,078

Balance as of April 1, 2022

62,508,517

4,663

279,054

(198,531
)

85,186

Share-based compensation to employees and non-employees

-

-

173

-

173

Issuance of ordinary shares upon vesting of RSUs by employees and non-employees

169,791

12

(12
)

-

-

Net loss

-

-

-

(4,446
)

(4,446
)
Balance as of June 30, 2022

62,678,308

4,675

279,215

(202,977
)

80,913

	Three Months Ended March 31,
	2023			2022
Revenues	$	1,230		$	876
Cost of revenues		659			611

Gross profit		571			265

Operating expenses:
Research and development, net		752			907
Sales and marketing		2,484			2,184
General and administrative		1,710			1,462

Total operating expenses		4,946			4,553

Operating loss		(4,375	)		(4,288	)
Financial expenses (income), net		(78	)		24

Loss before income taxes		(4,297	)		(4,312	)
Taxes on income		24			38

Net loss	$	(4,321	)	$	(4,350	)

Net loss per ordinary share, basic and diluted	$	(0.07	)	$	(0.07	)

Weighted average number of shares used in computing net loss per ordinary share, basic and diluted		59,515,524			62,493,496

The accompanying notes are an integral part of these condensed consolidated financial statements.

REWALK ROBOTICS LTD. AND SUBSIDIARIES

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share data)

Ordinary Shares

Additional
paid-in

Accumulated

Total
shareholders’

Number

Amount

capital

deficit

equity

Balance as of January 1, 2021

25,332,225

1,827

201,392

(181,445
)

21,774

Share-based compensation to employees and non-employees

-

-

368

-

368

Issuance of ordinary shares upon vesting of RSUs by employees and non-employees

132,571

11

(11
)

-

-

Issuance of ordinary shares in a private placement, net of issuance expenses in the amount of $3,679 (1)

10,921,502

832

35,489

-

36,321

Exercise of warrants (2)

9,814,754

724

13,094

-

13,818

Net loss

-

-

-

(6,203
)

(6,203
)
Balance as of June 30, 2021

46,201,052

3,394

250,332

(187,648
)

66,078

Balance as of January 1, 2022

62,480,163

4,661

278,903

(194,181
)

89,383

Share-based compensation to employees and non-employees

-

-

326

-

326

Issuance of ordinary shares upon vesting of RSUs by employees and non-employees

198,145

14

(14
)

-

-

Net loss

-

-

-

(8,796
)

(8,796
)
Balance as of June 30, 2022

62,678,308

4,675

279,215

(202,977
)

80,913

~~(1)~~

~~See Note 7e to the condensed consolidated financial statements.~~

~~(2)~~

~~See Note 7c to the condensed consolidated financial statements.~~

	Ordinary Shares						Additional paid-in			Treasury			Accumulated			Total shareholders’
	Number			Amount			capital			Shares			deficit			equity
Balance as of December 31, 2021		62,480,163		$	4,661		$	278,903		$	-		$	(194,181	)	$	89,383
Share-based compensation to employees and non-employees		-			-			153			-			-			153
Issuance of ordinary shares upon vesting of employees and non-employees RSUs		28,354			2			(2	)		-			-			-
Net loss		-			-			-			-			(4,350	)		(4,350	)
Balance as of March 31, 2022		62,508,517			4,663			279,054			-			(198,531	)		85,186

Balance as of December 31, 2022		60,090,298			4,489			279,857			(2,431	)		(213,750	)		68,165
Share-based compensation to employees and non-employees		-			-			304			-			-			304
Issuance of ordinary shares upon vesting of RSUs by employees and non-employees		122,056			9			(9	)		-			-			-
Treasury shares at cost		(730,350	)		(53	)		-			(576	)		-			(629	)
Net loss		-			-			-			-			(4,321	)		(4,321	)
Balance as of March 31, 2023		59,482,004		$	4,445		$	280,152		$	(3,007	)	$	(218,071	)	$	63,519

The accompanying notes are an integral part of these condensed consolidated financial statements.

REWALK ROBOTICS LTD. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

Six Months Ended
June 30,

2022

2021

Cash flows used in operating activities:

Net loss

$
(8,796
)

$
(6,203
)
Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation

110

141

Share-based compensation to employees and non-employees

326

368

Deferred taxes

(7
)

(11
)
Finance expense, net

164

-

Trade receivables, net

(281
)

(95
)
Prepaid expenses, operating lease right-of-use assets and other assets

(183
)

85

Inventories

(228
)

138

Trade payables

168

(285
)
Employees and payroll accruals

(177
)

(172
)
Deferred revenues

(37
)

(51
)
Operating lease liabilities and other liabilities

(436
)

(255
)
Net cash used in operating activities

(9,377
)

(6,340
)

Cash flows used in investing activities:

Purchase of property and equipment

(18
)

(11
)
Net cash used in investing activities

(18
)

(11
)

Cash flows from financing activities:

Issuance of ordinary shares in a private placement, net of issuance expenses paid in the amount of $3,582 (1)

-

36,418

Exercise of pre-funded warrants and warrants (1) (2)

-

13,818

Net cash provided by financing activities

-

50,236

Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash

(164
)
-
Increase (decrease) in cash, cash equivalents, and restricted cash

(9,395
)

43,885

Cash, cash equivalents, and restricted cash at beginning of period

89,050

21,054

Cash, cash equivalents, and restricted cash at end of period

$
79,491

$
64,939

Supplemental disclosures of non-cash flow information

Expenses related to offerings not yet paid (1)

$
-

$
97

Classification of other current assets to property and equipment, net

$
22

$
16

Classification of inventory to property and equipment, net

$
67

$
32

Classification of inventory to other current assets

$
109

$
26

Supplemental cash flow information:

Cash and cash equivalents

$
78,832

$
64,236

Restricted cash included in other long-term assets

659

703

Total Cash, cash equivalents, and restricted cash

$
79,491

$
64,939

~~(1)~~

~~See Note 7e to the condensed consolidated financial statements.~~

~~(2)~~

~~See Note 7c to the condensed consolidated financial statements.~~

	Three Months Ended March 31,
	2023			2022
Cash flows used in operating activities:
Net loss	$	(4,321	)	$	(4,350	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		36			53
Share-based compensation		304			153
Deferred taxes		-			1
Foreign currency remeasurement loss		11			-
Changes in assets and liabilities:
Trade receivables, net		504			21
Prepaid expenses, operating lease right-of-use assets and other assets		(1,370	)		(706	)
Inventories		(119	)		(325	)
Trade payables		23			81
Employees and payroll accruals		(769	)		(465	)
Deferred revenues		61			(34	)
Operating lease liabilities and other liabilities		407			(137	)
Net cash used in operating activities		(5,233	)		(5,708	)

Cash flows used in investing activities:
Purchase of property and equipment		-			(3	)
Net cash used in investing activities		-			(3	)

Cash flows from financing activities:
Purchase of treasury shares		(771	)		-
Net cash used in financing activities		(771	)		-

Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash		(11	)		-
Decrease in cash, cash equivalents, and restricted cash		(6,015	)		(5,711	)
Cash, cash equivalents, and restricted cash at beginning of period		68,555			89,050
Cash, cash equivalents, and restricted cash at end of period	$	62,540		$	83,339
Supplemental disclosures of non-cash flow information
Classification of inventory to property and equipment, net	$	-		$	51
Classification of other current assets to property and equipment, net	$	-		$	22
ROU assets obtained from new lease liabilities	$	513		$	-
Supplemental cash flow information:
Cash and cash equivalents	$	61,883		$	82,632
Restricted cash included in other long-term assets		657			707
Total Cash, cash equivalents, and restricted cash	$	62,540		$	83,339

The accompanying notes are an integral part of these condensed consolidated financial statements.

REWALK ROBOTICS LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1:GENERAL

ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date.

a.ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date.

b.RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) ReWalk Robotics GMBH. (“RRG”) incorporated under the laws of Germany on January 14, 2013.

b.
RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) ReWalk Robotics GMBH. (“RRG”) incorporated under the laws of Germany on January 14, 2013.

The Company is a medical device company that is designing, developing, and commercializing innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. Our initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury (“SCI Products”). These devices are robotic exoskeletons that are designed for individuals with paraplegia that use our patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury the ability to stand and walk again during everyday activities at home or in the community.

The Company ~~is designing, developing,~~has sought to expand its product offerings beyond the SCI Products through internal development and ~~commercializing robotic exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again.~~distribution agreements. The Company has developed ~~and is continuing to commercialize the ReWalk, an exoskeleton designed for individuals with paraplegia that uses~~ its ~~patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. The ReWalk system consists of a light wearable brace support suit~~ReStore Exo-Suit device, which ~~integrates motors at the joints, rechargeable batteries, an array of sensors and a computer-based control system to power knee and hip movement. Additionally, the Company developed and,~~it began commercializing in June ~~2019, started to commercialize the ReStore following receipt of European Union CE mark and United States Food and Drug Administration (“FDA”) clearance.~~2019. The ReStore is a powered, lightweight soft exo-suit intended for use induring the rehabilitation of individuals with lower limb disability due to stroke. During the second quarter of 2020, the Company signed two separate agreements to distribute additional product lines in the United States. The Company is the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to U.S. rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through VA hospitals. In the second quarter of 2020, the Company also became the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States; however, due to unsatisfactory sales performance of the MediTouch product lines, the Company terminated this agreement as of January 31, 2023. The Company will continue to evaluate other products for distribution or acquisition that can broaden its product offerings further to help individuals with neurological injury and disability.

The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in Germany and the United States, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with rehabilitation centers and the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI markets and sells products mainly in the United States. RRG markets and sells the Company’s products mainly in Germany and Europe.

During the second quarter of 2020, the Company finalized two separate agreements to distribute additional product lines in the U.S. market. The Company is the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United States and has distribution rights for the MYOLYN MyoCycle FES cycles to U.S. rehabilitation clinics and personal sales through the U.S. Department of Veterans Affairs (“VA”) hospitals. These new products have improved the Company’s product offering to clinics as well as patients within the VA as they both have similar clinician and patient profiles.

c.The worldwide spread of COVID-19 has resulted in a global economic slowdown and is expected to continue to disrupt general business operations until the disease is contained. This has had a negative impact on the Company’s sales and results of operations since the start of the pandemic, and the Company expects that it will continue to negatively affect its sales and results of operations; however, the Company is currently unable to predict the scale and duration of that impact. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update of its accounting estimates or judgments or revision of the carrying value of its assets or liabilities. This determination may change as new events occur and additional information is obtained. Actual results could differ from management’s estimates and judgments, and any such differences may be material to the Company’s financial statements.

REWALK ROBOTICS LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

As of March 31, 2023, the Company incurred a consolidated net loss of $4.3 million and has an accumulated deficit in the total amount of $218.1 million. The Company’s cash and cash equivalent as of March 31, 2023 totaled $61.9 million and the Company’s negative operating cash flow for the three months ended March 31, 2023 was $5.2 million. The Company has sufficient funds to support its operations for more than 12 months following the issuance date of its unaudited condensed consolidated financial statements for the three months ended March 31, 2023.

~~As of June 30, 2022, the Company incurred a consolidated net loss of $8.8~~ ~~million and has an accumulated deficit in the total amount of $203.0~~ ~~million. The Company’s cash and cash equivalent as of June 30, 2022 totaled $78.8~~ ~~million and the Company’s negative operating cash flow for the six months ended June 30, 2022 was $9.4~~ million. The Company has sufficient funds to support its operations for more than 12 months following the issuance date of its condensed consolidated unaudited financial statements for the three and six months ended June 30, 2022. The Company expects to incur future net losses and its transition to profitability is dependent upon, among other things, the successful development and commercialization of its products and product candidates, ~~and~~the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines, any of which, or in combination, would contribute to the achievement of a level of revenues adequate to support its cost structure. Until the Company achieves profitability or generates positive cash flows, it will continue to need to raise additional cash. ~~the~~The Company intends to fund future operations through cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants or a combination of the foregoing. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources and will continue to address its cost structure. Notwithstanding, there can be no assurance that the Company will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.

NOTE 2:UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting ~~principles and standards of the Public Company Accounting Oversight Board for interim financial information.~~principles. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In management’s opinion, the accompanying financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. The Company’s interim period results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year.

These financial statements and accompanying notes should be read in conjunction with the ~~2021~~2022 consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, ~~2021 filed with the SEC on February 24, 2022, as amended on May 2,~~ 2022 (the ~~“2021~~“2022 Form 10-K”). There have been no changes in the significant accounting policies from those that were disclosed in the ~~audited~~ consolidated financial statements for the fiscal year ended December 31, ~~2021~~2022 included in the ~~2021~~2022 Form 10-K, unless otherwise stated.

107

REWALK ROBOTICS LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 3:SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors.

Disaggregation of Revenues (in thousands)

	Three Months Ended March 31,
	2023		2022
Units placed	$	1,126	$	778
Spare parts and warranties		104		98
Total Revenues	$	1,230	$	876

Three Months Ended
June 30,

Six Months Ended
June 30,

2022

2021

2022

2021

Units placed

$
1,457

$
1,313

$
2,235

$
2,455

Spare parts and warranties

113

123

211

297

Total Revenues

$
1,570

$
1,436

$
2,446

$
2,752

~~REWALK ROBOTICS LTD. AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

Units placed

~~The~~During the periods for the three months ended March 31, 2023 and 2022, the Company ~~currently offers~~offered five products: (1) ReWalk Personal; (2) ReWalk Rehabilitation; (3) ReStore; (4) MyoCycle; and (5) MediTouch. Due to unsatisfactory sales performance of the MediTouch product lines, we terminated this agreement as of January 31, 2023.

ReWalk Personal and ReWalk Rehabilitation are ~~units for spinal cord injuries (“SCI Products”).~~ SCI Products, which are currently designed for everyday use by paraplegic individuals at home and in their ~~communities, and~~communities. The SCI Products are custom fitted for each user, as well as for use by ~~paraplegia~~paraplegic patients in the clinical rehabilitation environment, where they provide individuals access to valuable exercise and therapy. ReWalk Rehabilitation which is a ReWalk Personal 6.0 product sold with multiple sizes of our adjustable parts to allow different users the ability to train within a clinic.

ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment.

The Company also sells Distributed Products that include the MyoCycle, ~~device~~which uses Functional Electrical Stimulation (“FES”) technology, ~~to facilitate therapeutic exercise for persons with muscle weakness or paralysis caused by disorders like spinal cord injury, multiple sclerosis,~~ and ~~stroke.~~

~~The~~previously MediTouch ~~Tutor~~tutor movement biofeedback ~~product line includes~~devices. The Company markets the Arm, Hand, 3D and Leg Tutor devices. These devices are used by physical and occupational therapists to evaluate functional tasks during rehabilitation of neurologic disorders and can also be used by patients remotely at home.

Pursuant to two separate distribution agreements entered into during the second quarter of 2020, the Company now markets both the MediTouch and MyoCyle products (together the “Distributed Products”)Distributed Products in the United States for use at home or in clinic. On January 31, 2023, the ~~clinic.~~Company terminated the distribution agreement with MediTouch.

Units placed includes revenue from sales ~~or rental~~ of SCI Products, ReStore and the Distributed Products.

For units placed, the Company recognizes ~~revenues~~revenue when it transfers control and title has passed to the customer. Each unit placed is considered an independent, unbundled performance obligation. The Company generally does not grant a right of return for its products besides isolated cases where the Company assesses the likelihood of such event to occur based on the Company’s historical experience and estimates. The Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee.

REWALK ROBOTICS LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Spare parts and warranties

Spare parts are sold to private individuals, rehabilitation facilities and distributors. Revenue is recognized when the Company satisfies a performance obligation by transferring control over promised goods or services to the customer. Each part sold is considered an independent, unbundled performance obligation.

Warranties are classified as either an assurance type or a service type warranty. A warranty is considered an assurance type warranty if it provides the ~~consumer~~customer with assurance that the product will function as intended for a limited period of time. An assurance type warranty is not accounted for as a separate performance obligation under the revenue model.

~~In the beginning of 2018, the Company updated its service policy for~~ SCI Products to include a five-year ~~warranty compared to a period of two years that were included in the past for parts and services.~~warranty. The first two years are considered as an assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. ~~An assurance type warranty is not accounted for as separate performance obligations under the revenue model.~~ A service type warranty is either sold with a unit or separately for ~~units~~a unit for which the warranty has expired. ~~Revenue~~A service type warranty is ~~then~~accounted as a separate performance obligation and revenue is recognized ratably over the life of the warranty.

The ReStore device is offered with a two-year warranty which is considered as assurance type warranty.

The Distributed Products are ~~offered~~sold with an assurance-type warranty ~~that is covered by the vendor~~ ranging from one year to ten years depending on the specific product and part.

~~REWALK ROBOTICS LTD. AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

Contract balances (in thousands)

	June 30,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
Trade receivable, net (1)	$	866	$	585
Trade receivable, net of credit losses (1)					$	532	$	1,036
Deferred revenues (1) (2)	$	1,145	$	1,182	$	1,252	$	1,191

(1)

Balance presented net of unrecognized revenues that were not yet collected.

(2)

During the ~~six~~three months ended ~~June 30, 2022, $200~~March 31, 2023, $128 thousand of the December 31, ~~2021,~~2022 deferred revenues balance was recognized as revenues.

Deferred revenue is ~~comprised mainly~~composed primarily of unearned revenue related to service type warranty ~~but also includes~~obligations as well as other ~~offerings for~~advances and payments which the Company received from customers prior to satisfying the performance obligation, for which revenue has not yet been ~~paid in advance and earns revenue when the Company transfers control of the product or service.~~recognized.

The Company’s ~~unfilled~~unearned performance obligations as of ~~June 30, 2022,~~March 31, 2023 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1.2 million, which iswill be fulfilled over one to five years.

Purchase commitments:

a.~~Purchase commitments:~~

TheThe Company has contractual obligations to purchase goods from its contract manufacturer as well as raw materials from different vendors. Purchase obligations do not include contracts that may be canceled without penalty. As of ~~June 30, 2022,~~March 31, 2023, non-cancelable outstanding obligations amounted to approximately ~~$1.1~~$2.1 million.

b.~~Operating lease commitment:~~

~~(i)~~The Company operates from leased facilities in Israel, the United States and Germany. These leases expire between 2022 and 2023. A portion of the Company’s facilities leases is generally subject to annual changes in the Consumer Price Index (the “CPI”). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.

~~(ii)~~RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2022 and 2025. A subset of the Company’s cars leases is considered variable. The variable lease payments for such cars leases are based on actual mileage incurred at the stated contractual rate. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $23 thousand as of June 30, 2022.

The Company's future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company's condensed consolidated balance sheets as of June 30, 2022, are as follows (in thousands):

2022

$
334

2023

514

2024 47
2025

7

Total lease payments

902

Less: imputed interest

(85
)
Present value of future lease payments

817

Less: current maturities of operating leases

(610
)
Non-current operating leases

$
207

Weighted-average remaining lease term (in years)

1.46

Weighted-average discount rate

12.5
%

b.
Operating lease commitment:

(i)

The Company operates from leased facilities in Israel, the United States and Germany. These leases expire in 2025. A portion of the Company’s facilities leases is generally subject to annual changes in the Consumer Price Index (the “CPI”). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred.

(ii)

RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates between 2023 and 2026. A subset of the Company’s car leases is considered variable. The variable lease payments for such cars leases are based on actual mileage incurred at the stated contractual rate. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $21 thousand as of March 31, 2023.

The Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company's condensed consolidated balance sheets as of March 31, 2023 are as follows (in thousands):

2023	$	503
2024		638
2025		295
2026		1
Total lease payments		1,437
Less: imputed interest		(156	)
Present value of future lease payments		1,281
Less: current maturities of operating leases		(624	)
Non-current operating leases	$	657
Weighted-average remaining lease term (in years)		2.18
Weighted-average discount rate		9.9	%

Lease expense under the Company’s operating leases was ~~$184~~$192 thousand and ~~$178~~$179 thousand for the three months ended ~~June 30,~~March 31, 2023 and 2022, ~~and 2021, respectively. For the six months ended June 30, 2022, and 2021, the lease expense was $363 thousand and $364 thousand,~~ respectively.

1612

REWALK ROBOTICS LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Royalties:

The Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (“IIA”).

Since the Company’s inception through March 31, 2023, the Company received funding from the IIA in the total amount of $2.3 million. Out of the $2.3 million in funding from the IIA, a total amount of $1.6 million were royalty-bearing grants, $400 thousand was received in consideration of 209 convertible preferred A shares, which converted after the Company’s initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1, while $349 thousand was received without future obligation. The Company is obligated to pay royalties to the IIA, amounting to 3% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required.

Additionally, the License Agreement requires the Company to pay Harvard royalties on net sales, see Note 6 below for more information about the Collaboration Agreement and the License Agreement.

As of March 31, 2023, the Company paid royalties to the IIA in the total amount of $110 thousand.

Royalties expenses in cost of revenues were $0 and $3 thousand for the three months ended March 31, 2023 and 2022, respectively.

As of March 31, 2023, the contingent liability to the IIA amounted to $1.6 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases:

(a)

the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the R&D activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) If such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient.

c.REWALK ROBOTICS LTD. AND SUBSIDIARIES~~Royalties:~~

~~The~~ Company’s research and development efforts are financed, in part, through funding from the Israel Innovation Authority (the “IIA”) and the Israel-U.S. Binational Industrial Research and Development Foundation (“BIRD”). During the three months ended June 30, 2022, the Company received $~~184~~ ~~thousand from the IIA to fund its research and development efforts.~~

Since the Company’s inception through June 30, 2022, the Company received funding from the IIA and BIRD in the total amount of $2.15 million and $500 thousand, respectively. Out of the $2.15 million in funding from the IIA, a total amount of $1.57 million were royalty-bearing grants (as of June 30, 2022, the Company paid royalties to the IIA in the total amount of $105 thousand), a total amount of $400 thousand was received in consideration of 209 convertible preferred A shares, which were converted after the Company’s initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1, while a total amount of $184 thousand was received without future obligation. The Company is obligated to pay royalties to the IIA, amounting to 3% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received.

The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required.

Additionally, the Exclusive License Agreement between the Company and Harvard University’s Wyss Institute for Biologically Inspired Engineering ("Harvard") requires the Company to pay Harvard royalties on net sales. See note 6 below for more information about the Collaboration Agreement and the License Agreement.

Royalties expenses in cost of revenue were $1 and $6 thousand for the three months ended June 30, 2022 and 2021, respectively. For the six months ended June 30, 2022, and 2021, the royalties expenses were $4 thousand and $6 thousand, respectively.

As of June 30, 2022, the contingent liability to the IIA amounted to $1.6 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases:

(a) the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the research and development activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) if such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient.

d.~~Liens:~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

~~The fair value of RSUs granted is determined based on the price of the Company's ordinary shares on the date of grant.~~

RSUs generally vest over four years, with certain RSUs to non-employee directors vesting quarterly over one year. Any RSUs that is canceled before the vesting becomes available for future grants under the 2014 Plan.

Issuance date	Warrants outstanding		Exercise price per warrant		Warrants outstanding and exercisable		Contractual term
	(number)				(number)
December 31, 2015 (1)		4,771	$	7.500		4,771	See footnote (1)
December 28, 2016 (2)		1,908	$	7.500		1,908	See footnote (1)
November 20, 2018 (3)		126,839	$	7.500		126,839	November 20, 2023
November 20, 2018 (4)		106,680	$	9.375		106,680	November 15, 2023
February 25, 2019 (5)		45,600	$	7.187		45,600	February 21, 2024
April 5, 2019 (6)		408,457	$	5.140		408,457	October 7, 2024
April 5, 2019 (7)		49,015	$	6.503		49,015	April 3, 2024
June 5, 2019, and June 6, 2019 (8)		1,464,665	$	7.500		1,464,665	June 5, 2024
June 5, 2019 (9)		87,880	$	9.375		87,880	June 5, 2024
June 12, 2019 (10)		416,667	$	6.000		416,667	December 12, 2024
June 10, 2019 (11)		50,000	$	7.500		50,000	June 10, 2024
February 10, 2020 (12)		28,400	$	1.250		28,400	February 10, 2025
February 10, 2020 (13)		105,840	$	1.563		105,840	February 10, 2025
July 6, 2020 (14)		448,698	$	1.760		448,698	January 2, 2026
July 6, 2020 (15)		296,297	$	2.278		296,297	January 2, 2026
December 8, 2020 (16)		586,760	$	1.340		586,760	June 8, 2026
December 8, 2020 (17)		108,806	$	1.792		108,806	June 8, 2026
February 26, 2021 (18)		5,460,751	$	3.600		5,460,751	August 26, 2026
February 26, 2021 (19)		655,290	$	4.578		655,290	August 26, 2026
September 29, 2021 (20)		8,006,759	$	2.000		8,006,759	March 29, 2027
September 29, 2021 (21)		960,811	$	2.544		960,811	September 27, 2026
		19,420,894				19,420,894

	(1)	Represents warrants for ordinary shares issuable upon an exercise price of ~~$7.50~~$7.500 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited ~~or Kreos,~~(“Kreos”) in connection with a loan made by Kreos to usthe Company and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of usthe Company with or into, or the sale or license of all or substantially all the assets or shares of usthe Company to, any other entity or person, other than a ~~wholly-owned~~wholly owned subsidiary of ~~us,~~the Company, excluding any transaction in which the Company’s shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of ~~June 30, 2022.~~March 31, 2023.

	(2)	Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.

	(3)	Represents common warrants that were issued as part of the Company’s follow-on public offering in November 2018.

~~REWALK ROBOTICS LTD. AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~


(4)	Represents common warrants that were issued to the underwriters as compensation for their role in the Company’s follow-on public offering in November 2018.

	(5)	Represents warrants that were issued to the exclusive placement agent as compensation for its role in the Company’s follow-on public offering in February 2019.

REWALK ROBOTICS LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

	(6)	Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in April 2019.

	(7)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s April 2019 registered direct offering.

	(8)	Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019, and June 6, 2019, respectively.

	(9)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 warrant exercise agreement and concurrent private placement of warrants.

	(10)	Represents warrants that were issued to certain institutional investors in a warrant exercise agreement in June 2019.

	(11)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s June 2019 registered direct offering and concurrent private placement of warrants.

	(12)	Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. ~~During the year ended December~~As of March 31, ~~2021,~~2023, 3,740,100 warrants were exercised for total consideration of $4,675,125. During the three months that ended March 31, 2023, no warrants were exercised.

	(13)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. ~~During the year ended December~~As of March 31, ~~2021,~~2023, 230,160 warrants were exercised for total consideration of $359,625. During the three months that ended March 31, 2023, no warrants were exercised.

	(14)	Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. ~~During the year ended December~~As of March 31, ~~2021,~~2023, 2,020,441 warrants were exercised for total consideration of $3,555,976. During the three months that ended March 31, 2023, no warrants were exercised.

	(15)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.


	(16)	Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in December 2020. ~~During the year ended December~~As of March 31, ~~2021,~~2023, 3,598,072 warrants were exercised for total consideration of $4,821,416. During the three months that ended March 31, 2023, no warrants were exercised.

	(17)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s December 2020 private placement. ~~During the year ended December~~As of March 31, ~~2021,~~2023, 225,981 warrants were exercised for total consideration of $405,003. During the three months that ended March 31, 2023, no warrants were exercised.

	(18)	Represents warrants that were issued to certain institutional purchasers in a private placement in our private placement offering of ordinary shares in February 2021.

~~REWALK ROBOTICS LTD. AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~


(19)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2021 private ~~placement offering in February 2021.~~placement.

	(20)	Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in September 2021.

	(21)	Represents warrants that were issued to the placement agent as compensation for its role in the Company’s September 2021 registered direct offering.

A~~s of June 30, 2022, a total of 9,814,754 previously issued warrants with exercise prices ranging from $1.25 to $1.79 have been exercised for total gross proceeds of approximately $13.8 million.~~

NOTE 9:GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA

Summary information about geographic areas:

ASCASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of 1one reportable segment and derives revenues from selling ~~units~~systems and ~~services (see Note 1 for a brief description of the Company’s business).~~services. The following is a summary of revenues within geographic areas (in thousands):

      Three Months Ended
June 30,

Six Months Ended
June 30,

2022

2021

2022

2021

Revenues based on customer’s location:

United States
$ 578 $ 654
$
798

$
1,130

Europe
888 726
1,535

1,563

Asia-Pacific
103 55
111

57

Africa
1 1
2

2

Total revenues
$ 1,570 $ 1,436
$
2,446

$
2,752

~~REWALK ROBOTICS LTD. AND SUBSIDIARIES~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)~~

	Three Months Ended March 31,
	2023		2022
Revenues based on customer’s location:
United States	$	877	$	220
Europe		324		647
Asia-Pacific		28		8
Africa		1		1
Total revenues	$	1,230	$	876

	June 30,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
Long-lived assets by geographic region (*):
Israel	$	580	$	629	$	704	$	757
United States		375		493		675		231
Germany		70		43		31		44
	$	1,025	$	1,165	$	1,410	$	1,032

*(*)

Long-lived assets are comprised of property and equipment, net, and operating lease right-of-use assets.


	Six Months Ended June 30,
	~~2022~~			~~2021~~
~~Major customer data as a percentage of total revenues:~~
~~Customer A~~		~~20.4~~	%		*	)
~~Customer B~~		~~11.7~~	%		-

REWALK ROBOTICS LTD. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

	Three Months Ended March 31,
	2023			2022
Major customer data as a percentage of total revenues:
Customer A		23	%		18	%
Customer B		10	%		*	)
Customer C		10	%		*	)
Customer D		10	%		*	)
Customer E		*	)		14	%
Customer F		*	)		13	%
Customer G		*	)		11	%
Customer H		*	)		10	%
Customer I		*	)		10	%

*) Less than 10%.

~~NOTE 10:~~ ~~SUBSEQUENT EVENTS~~

In ~~June 2022, the Company announced that its Board of Directors~~ ~~(the “Board”)~~ ~~had approved a program to repurchase up to $8.0 million of the Company’s ordinary shares, par value NIS 0.25 per share~~, subject to receipt of Israeli court approval. In July 2022, the Company announced that it had received approval from an Israeli court for the share repurchase program, valid through January 20, 2023.

2622

ITEM 2. ~~MANAGEMENT’S~~ MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operation should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes included elsewhere in this quarterly report and with our audited consolidated financial statements included in our Form 10-K for the year ended December 31, ~~2021~~2022 as filed with the ~~SEC~~Securities and Exchange Commission (“SEC”) on February ~~24, 2022~~23, 2023 and amended on May ~~2, 2022~~1, 2023 (the ~~“2021~~“2022 Form 10-K”). In addition to historical condensed financial information, the following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. For a discussion of factors that could cause or contribute to these differences, see “Special Note Regarding Forward-Looking Statements” above.

Overview

We are ~~an innovative~~a medical device company that is designing, developing, and commercializing innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. Our initial product offerings were the SCI Products. These devices are robotic exoskeletons that ~~allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. We have developed and~~ are ~~continuing to commercialize our ReWalk Personal and ReWalk Rehabilitation devices for individuals with spinal cord injury (“SCI Products”), which are exoskeletons~~ designed for individuals with paraplegia that use our patented tilt-sensor technology and an ~~on-board~~onboard computer and motion sensors to drive motorized legs that power movement.

These SCI Products allow individuals with spinal cord injury the ability to stand and walk again during everyday activities at home or in the community. In ~~May 2021,~~March 2023, we received 510(k) clearance from the ~~FDA granted breakthrough design designation to~~U.S. Food and Drug Administration (“FDA”) for the ReWalk Personal 6.0 to enable the stairs ~~feature. In June 2022, we submitted a 510(k) application to the FDA for our ReWalk Personal exoskeleton system seeking clearance for the use of ReWalk Personal units~~functionality and add uses on stairs and curbs to the indication for use for the device in the ~~United States, which is currently under review.~~

U.S. The clearance permits U.S. customers to participate in more walking activities in their daily lives where stairs or curbs may have previously limited them. This feature has been available in Europe since initial CE Clearance, and real-world data from a cohort of 47 European users throughout a period of over seven years and consisting of over 18,000 stair steps was collected to demonstrate the safety and efficacy of this feature and support the FDA submission.

We have ~~also~~sought to expand our product offerings beyond the SCI Products through internal development and distribution agreements. We have developed ~~and began commercializing~~ our ReStore Exo-Suit device, which we began commercializing in June 2019. The ReStore is a powered, lightweight soft exo-suit intended for use induring the rehabilitation of individuals with lower limb ~~disability~~disabilities due to stroke. During the second quarter of 2020, we finalized and moved to implement two separate agreements to distribute additional product lines in the United States. We are the exclusive distributor of the MYOLYN MyoCycle FES Pro cycles to U.S. ~~market. We will be~~rehabilitation clinics and for the MyoCycle Home cycles available to US veterans through the U.S. Department of Veterans Affairs (“VA”) hospitals. In the second quarter of 2020, we also became the exclusive distributor of the MediTouch Tutor movement biofeedback systems in the United ~~States~~States; however, due to unsatisfactory sales performance of the MediTouch product lines, we terminated this agreement as of January 31, 2023. We refer to the MediTouch and MyoCycle devices as our “Distributed Products.” We will ~~also have~~continue to evaluate other products for distribution ~~rights for the MYOLYN MyoCycle FES cycles to U.S. rehabilitation clinics and personal sales through U.S. Department of Veteran Affairs (“VA”) hospitals. These new products will improve~~or acquisition that can broaden our product ~~offering~~offerings further to ~~clinics~~help individuals with neurological injury and disability.

We are in the research stage of ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke, and we are currently evaluating the reimbursement landscape and the potential clinical impact of this device. This product would be a complementary product to ReStore as ~~well as patients within~~it provides active assistance to the ~~VA as they both have similar clinician~~ankle during plantar flexion and ~~patient profile.~~

dorsiflexion for gait and mobility improvement in the home environment, and it received Breakthrough Device Designation from the FDA in November 2021. Further investment in the development path of the ReBoot has been temporarily paused in 2023 pending further determination about the clinical and commercial opportunity of this device.

Our principal markets are the United States and Europe. In Europe, we have a direct sales operation in Germany ~~and the United Kingdom~~ and work with distribution partners in certain other major countries. We have offices in Marlborough, Massachusetts, Berlin, Germany and Yokneam, Israel, from where we operate our ~~business from.~~

business.

We have in the past generated and expect to generate in the future ~~revenues~~revenue from a combination of third-party payors ~~self-payors, including~~(including private and government ~~employers,~~payors) and ~~institutions.~~self-pay individuals. While a broad uniform policy of coverage and reimbursement by third-party commercial payors currently does not exist in the United States for ~~electronic~~ exoskeleton technologies such as the ReWalk Personal Exoskeleton, we are pursuing various paths of reimbursement and support fundraising efforts by institutions and ~~clinics. In~~clinics, such as the VA policy that was issued in December 2015 ~~the VA issued a national policy~~ for the evaluation, training, and procurement of ReWalk Personal exoskeleton systems for all qualifying veterans suffering from SCI across the United States. ~~The VA policy is the first national coverage policy in the United States for qualifying individuals who~~

We have ~~suffered spinal cord injury. As of June 30, 2022, we had placed 30 units as part of the VA policy.~~

~~According to a 2017 report published by~~also been pursuing updates with the Centers for Medicare and Medicaid Services (“CMS”), to clarify the Medicare coverage category (i.e., benefit category) applicable for personal exoskeletons. In 2021, the National Spinal Cord Injury Statistical Center (“NSCISC”) reported the Medicare and Medicaid are the primary payors for approximately ~~55%~~56% of the spinal cord injury population which are at least five years post their injury ~~date are covered by CMS.~~date. In July 2020, following a successful submission and hearing process, a code was issued for ReWalk Personal ~~6.0~~Exoskeleton (effective October 1, 2020), which ~~might later~~may be ~~followed by coverage policy~~used for purposes of ~~CMS. On June 8, 2022, CMS held its First Biannual Healthcare Common Procedure Coding System (HCPCS) public meeting~~claim submission to ~~discuss several preliminary benefit~~Medicare, Medicaid, and ~~payment decisions under the new Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) rules. Included on the agenda was~~other payors. We are currently seeking a ~~discussion of the~~nationwide Medicare benefit category determination from CMS to designate the relevant Medicare benefit category. CMS has stated that, until a nationwide benefit category determination is issued, coverage and payment ~~determination for~~can be adjudicated on a case-by-case basis by the ~~ReWalk Personal 6.0. No preliminary determination was made during the meeting, and we are currently awaiting further feedback from CMS, which we expect to receive during the second half of 2022.~~

~~Additionally, to date, several private insurers in the United States and Europe have provided reimbursement for ReWalk in certain cases.~~ Medicare Administrative contractors (“MACs”).

In Germany, we continue to make progress toward achieving ~~ReWalk~~ coverage from the various government, private and worker’s compensation ~~payors.~~payors for our SCI products. In September 2017, each of German insurer BARMER GEK (“~~Barmer”~~BARMER”) and national social accident insurance provider Deutsche Gesetzliche Unfallversicherung (“DGUV”), indicated that they will provide coverage to users who meet certain inclusion and exclusion criteria. In February 2018, the head office of German ~~statutory health insurance~~Statutory Health Insurance (“SHI”), Spitzenverband (“GKV”) confirmed their decision to list the ReWalk Personal ~~6.0 exoskeleton~~Exoskeleton system in the German Medical Device Directory. This decision means that ReWalk ~~will be~~is listed among all medical devices for compensation, which SHI providers can procure for any approved beneficiary on a case-by-case basis. During the year 2020 and 2021, we announced several new agreements with German SHIs, ~~such as~~including TK and DAK Gesundheit, ~~and others~~ as well as the first German Private Health Insurer (“PHI”) ~~that have chosen to enter into an agreement that outlines~~, which outline the process of obtaining ~~a device~~our devices for eligible insured ~~patient.~~patients. We are also currently working with several additional SHIs ~~and PHIs~~ on securing a formal operating contract that will establish the process of obtaining a ReWalk Personal ~~6.0 device~~Exoskeleton for their beneficiaries within their system.

Additionally, to date, several private insurers in the United States and Europe are providing reimbursement for ReWalk in certain cases.

2724

~~Second~~First Quarter ~~2022~~2023 and Subsequent Period Business Highlights

●•

Total revenue for the ~~second~~first quarter of 2023 was $1.2 million, as compared to $0.9 million in the first quarter of 2022, ~~was $1.6 million, compared to $1.4 million in the second quarter of 2021;~~

up 40%;

●•

~~Strong cash position with $78.8 million~~

Gross margin was 46.4% in Q1’23, as ~~of June 30, 2022;~~

compared to 30.3% in Q1’22, a 16 percentage point increase;

●•

~~The Company’s operating~~

Operating expenses were ~~$5.1~~$4.9 million in the ~~second~~first quarter of ~~2022,~~2023, as compared to ~~$3.9~~$4.6 million in the ~~second~~first quarter of ~~2021;~~

2022;

	●•	In June 2022, the Company announced that its Board of Directors (the “Board”) had approved a program to repurchase up to $8.0 million of the Company’s ordinary shares, par value NIS 0.25 per share, subject to receipt of Israeli court approval. In July 2022, the Company announced that it had received approval from an Israeli court for the share repurchase program, valid through January 20, 2023. The process to begin repurchasing shares is underway;
	●	~~On June 8th, the Company presented before CMS at its Healthcare Common Procedure Coding System (HCPCS) meeting, detailing why CMS should promptly assign~~March 2023, the ReWalk Personal ~~Prosthetic~~ Exoskeleton totechnology received 510(k) clearance from the ~~“artificial leg” prosthetic benefit category. No preliminary determination was made during~~U.S. Food and Drug Administration (“FDA”) for use on stairs and curbs, making it the ~~meeting, and ReWalk is currently awaiting further feedback from CMS, which it expects~~only personal exoskeleton to receive ~~during the second half of 2022.~~ FDA clearance for this indication.

~~Evolving~~ COVID-19 Pandemic Impact

The impact of the COVID-19 pandemic ~~has~~ resulted ~~in, and will likely continue to result~~ in significant disruptions to the global economy and the capital markets, as well as our business. ~~A significant number of our global suppliers, vendors, distributors~~

For example, shut-downs and manufacturing facilities are located in regions that have been affected by the pandemic. Those operations have been materially adversely affected by restrictive government and private enterprise measures implementedother limitations imposed in response to the pandemic, which in turn, has negatively impacted our operations. Despite the distribution of COVID-19 vaccines, new and occasionally more virulent variants (including the BA.4 and BA.5 subvariants) of the virus that causes COVID-19, including the Delta and Omicron variants, have emerged, and there is significant uncertainty as to how the countries in which we do business will continue to respond to such outbreaks, including whether there will be future partial or total shutdowns, which would adversely affect our business.

~~Although we have seen the U.S. and German markets start to fully open for the first time since the pandemic started in early 2020, allowing us to restart market development and access programs, the~~ COVID-19 pandemic ~~has continued to affect~~adversely affected our ability to engage with our ~~SCI Products, ReStore and Distributed Products~~ existing customers ~~conduct trials of~~and perform product ~~candidates, deliver ordered units or repair existing systems~~repairs, as well as to identify and provide ~~training for our products~~product demonstrations and trainings to potential new ~~patients,~~customers, who ~~have~~ largely remained at home ~~due to~~during local movement restrictions, and to rehabilitation centers, which ~~have~~ temporarily shifted priorities and responses to pandemic-related medical equipment. In addition, staffing shortages within the healthcare system itself ~~has~~ resulted in a diminished demand for our SCI Products as the attention of healthcare workers and potential patients ~~has~~ turned elsewhere. As

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our condensed financial statements requires us to make estimates, judgments and assumptions that can affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, judgments and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. Besides the estimates identified above that are considered critical, we make many other accounting estimates in preparing our condensed financial statements and related disclosures. See Note 2 to our audited consolidated financial statements included in our ~~2021~~2022 Form 10-K for a description of the significant accounting policies that we used to prepare our consolidated financial statements.

There have been no material changes to our critical accounting policies or our critical judgments from the information provided in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies” of our ~~2021~~2022 Form 10-K, except for the updates provided in Note 3 of our unaudited condensed consolidated financial statements set forth in “Part I, Item 1. Financial Statements” of this quarterly report.

Recent Accounting Pronouncements

See Note 3 to our unaudited condensed consolidated financial statements set forth in “Part I, Item 1. Financial Statements” of this quarterly report for information regarding new accounting pronouncements.

3229

Liquidity and Capital Resources

Sources of Liquidity and Outlook

Since inception, we have funded our operations primarily through the sale of certain of our equity securities and convertible notes to investors in private placements, the sale of our ordinary shares in public offerings and the incurrence of bank debt.

During the ~~six~~three months ended ~~June 30, 2022,~~March 31, 2023, we incurred a consolidated net loss of ~~$8.8~~$4.3 million and ~~as of June 30, 2022, we had~~have an accumulated deficit in the total amount of ~~$203.0~~$218.1 million. Our cash and cash ~~equivalents~~equivalent as of ~~June 30, 2022, were $78.8~~March 31, 2023, totaled $61.9 million and our negative operating cash flow for the ~~six~~three months ended ~~June 30, 2022,~~March 31, 2023, was ~~$9.4~~$5.2 million. We ~~believe we~~ have sufficient funds to support our ~~operations~~operation for more than 12 months following the issuance date of our condensed consolidated unaudited financial statements for the three ~~and six~~ months ended ~~June 30, 2022.~~March 31, 2023.

We expect to incur future net losses and our transition to profitability is dependent upon, among other things, the successful development and commercialization of our products and product candidates, the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines, any of which, or in combination, would contribute to the achievement of a level of revenues adequate to support our cost structure. Until we achieve profitability or generate positive cash flows, we will continue to need to raise additional ~~cash.~~ cash from time to time.

We intend to fund future operations through cash on hand, additional private and/or public offerings of debt or equity securities, cash exercises of outstanding warrants or a combination of the foregoing. In addition, we may seek additional capital through arrangements with strategic partners or from other sources and we will continue to address our cost structure. Notwithstanding, there can be no assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.

Our anticipated primary uses of cash are (i) sales, marketing and reimbursement expenses related to market development activities of our ReStore and Personal 6.0 devices, broadening third-party payor and CMS coverage for our ReWalk Personal device and commercializing our new product lines added through distribution agreements; (ii) research and development of our lightweight exo-suit technology for potential home personal health utilization for multiple indications and future generation designs for our spinal cord injury device; (iii) routine product updates; (iv) general corporate purposes, including working capital needs; and (v) potential acquisitions of business. Our future cash requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities, the timing and extent of our spending on research and development efforts and international expansion. If our current estimates of revenue, expenses or capital or liquidity requirements change or are inaccurate, we may seek to sell additional equity or debt securities, arrange for additional bank debt financing, or refinance our indebtedness. There can be no assurance that we will be able to raise such funds at all or on acceptable terms.

Equity Raises

Use of Form S-3

Beginning with the filing of our Form 10-K on February 17, 2017, we were subject to limitations under the applicable rules of Form S-3, which constrained our ability to secure capital ~~pursuant~~with respect to ~~our ATM Offering Program (as defined below) or other~~ public offerings pursuant to our effective Form S-3. These rules limit the size of primary securities offerings conducted by issuers with a public float of less than $75 million to no more than one-third of their public float in any 12-month period. At the time of filing our ~~annual report for the year ended December 31, 2020,~~2022 Form 10-K, on February 23, 2023, we were ~~no longer~~ subject to these limitations, because our public float ~~had reached~~did not reach at least $75 million in the 60 days preceding the filing of ~~that annual report. Likewise, because~~ our ~~public float was at least $75 million within the 60 days preceding the date of our 2021 Annual Report, we are not currently subject to these limitations, and~~2022 Form 10-K. We will continue to ~~not~~ be subject to these limitations for the remainder of the ~~2022~~2023 fiscal year and until the earlier of such time as our public float reaches at least $75 million or when we file our next annual report for the year ended December 31, ~~2022,~~2023, at which time we will be required to re-test our status under these rules. If our public float ~~subsequently drops~~is below $75 million as of the filing of our next annual report on Form 10-K, or at the time we file a new Form S-3, we will ~~become~~continue to be subject to these limitations, ~~again,~~ until the date that our public float again reaches $75 million. These limitations do not apply to secondary offerings for the resale of our ordinary shares or other securities by selling shareholders or to the issuance of ordinary shares upon conversion by holders of convertible securities, such as warrants. We have registered up to $100 million of ordinary shares warrants and/or debt securities and certain other outstanding securities with registration rights on our ~~new~~ registration statement on Form S-3, which was declared effective by the SEC in May 2022.

~~Equity Offerings and Warrant Exercises~~

On February 19, 2021, we entered into a purchase agreement with certain institutional and other accredited investors for the issuance and sale of 10,921,502 ordinary shares, par value NIS 0.25 per share at $3.6625 per ordinary share and warrants to purchase up to an aggregate of 5,460,751 ordinary shares with an exercise price of $3.6 per share, exercisable from February 19, 2021, until August 26, 2026. Additionally, we issued warrants to purchase up to 655,290 ordinary shares, with an exercise price of $4.578125 per share, exercisable from February 19, 2021, until August 26, 2026, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our February 2021 Offering.

On September 27, 2021, we signed a purchase agreement with certain institutional investors for the issuance and sale of 15,403,014 ordinary shares, pre-funded warrants to purchase up to an aggregate of 610,504 ordinary shares and ordinary warrants to purchase up to an aggregate of 8,006,759 ordinary shares at an exercise price of $2.00 per share. The pre-funded warrants have an exercise price of $0.001 per ordinary share and are immediately exercisable and can be exercised at any time after their original issuance until such pre-funded warrants are exercised in full. Each ordinary share was sold at an offering price of $2.035 and each pre-funded warrant was sold at an offering price of $2.034 (equal to the purchase price per ordinary share minus the exercise price of the pre-funded warrant). The offering of the ordinary shares, the pre-funded warrants and the ordinary shares that are issuable from time to time upon exercise of the pre-funded warrants was made pursuant to our shelf registration statement on Form S-3 initially filed with the SEC on May 9, 2019, and declared effective by the SEC on May 23, 2019, and the ordinary warrants were issued in a concurrent private placement. The ordinary warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending five and one-half years from the date of issuance. All of the pre-funded warrants were exercised in full on September 27, 2021, and the offering closed on September 29, 2021. Additionally, we issued warrants to purchase up to 960,811 ordinary shares, with an exercise price of $2.5438 per share, exercisable from September 27, 2021, until September 27, 2026, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our September 2021 private placement offering.

~~As of June 30, 2022, a total of 9,814,754 previously issued warrants with exercise prices ranging from $1.25 to $1.79 have been exercised for total gross proceeds of approximately $13.8 million.~~

~~ATM Offering Program~~

On May 10, 2016, we entered into our Equity Distribution Agreement with Piper Jaffray, as amended on May 9, 2019, pursuant to which we may offer and sell, from time to time, ordinary shares having an aggregate offering price of up to $25.0 million through Piper Jaffray acting as our agent (the “ATM Offering Program”). Subject to the terms and conditions of the Equity Distribution Agreement, Piper Jaffray will use its commercially reasonable efforts to sell on our behalf all of the ordinary shares requested to be sold by us, consistent with its normal trading and sales practices. Piper Jaffray may also act as principal in the sale of ordinary shares under the Equity Distribution Agreement. Such sales may be made under our Form S-3 in what may be deemed “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act, directly on or through the Nasdaq Capital Market, to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in privately negotiated transactions.

Piper Jaffray is entitled to compensation at a fixed commission rate of 3% of the gross sales price per share sold through it as agent under the Equity Distribution Agreement. Where Piper Jaffray acts as principal in the sale of ordinary shares under the Equity Distribution Agreement, such rate of compensation will not apply, but in no event will the total compensation of Piper Jaffray, when combined with the reimbursement of Piper Jaffray for the out-of-pocket fees and disbursements of its legal counsel, exceed 8.0% of the gross proceeds received from the sale of the ordinary shares.

3430

We may instruct Piper Jaffray not to sell ordinary shares if the sales cannot be effected at or above the price designated by us in any instruction. We or Piper Jaffray may suspend an offering of ordinary shares under the ATM Offering Program upon proper notice and subject to other conditions, as further described in the Equity Distribution Agreement. Additionally, the ATM Offering Program will terminate on the earlier of (i) the sale of all ordinary shares subject to the Equity Distribution Agreement, (ii) the date that is three years after a new registration statement on Form S-3 goes effective, (iii) our becoming ineligible to use Form S-3 and (iv) termination of the Equity Distribution Agreement by the parties. The Equity Distribution Agreement may be terminated by Piper Jaffray or us at any time on the close of business on the date of receipt of written notice, and by Piper Jaffray at any time in certain circumstances, including any suspension or limitation on the trading of our ordinary shares on the Nasdaq Capital Market, as further described in the Equity Distribution Agreement. We temporarily suspended use of the ATM Offering Program on February 20, 2019 to facilitate our February 2019 “best efforts” public offering. As of September 30, 2020, we had sold 302,092 ordinary shares under the ATM Offering Program for net proceeds to us of $14.5 million (after commissions, fees, and expenses). Additionally, as of that date, we had paid Piper Jaffray compensation of $471 thousand and had incurred total expenses (including such commissions) of approximately $1.2 million in connection with the ATM Offering Program. No sales were made under the ATM Offering Program during the year ended December 31, 2021 or during the six months ended June 30, 2022.

We intend to continue using the at-the-market offering or similar continuous offering programs opportunistically to raise additional funds, although we are currently subject to restrictions on using the ATM Offering Program with Piper Jaffray. Under our September 2021 purchase agreement with certain investors, equity or debt securities convertible into, or exercisable or exchangeable for, ordinary shares at a conversion price, exercise price or exchange price which floats with the trading price of the ordinary shares or which may be adjusted after issuance upon the occurrence of certain events or (ii) enter into any agreement, including an equity line of credit, whereby the Company may issue securities at a future-determined price, other than an at–the-market facility with the placement agent, H.C. Wainwright & Co, LLC, beginning on March 29, 2022. Such limitations may inhibit our ability to access capital efficiently.

Share Repurchase Program

In June 2022, we announced that our Board ~~of Directors (our “Board”)~~ had approved a program to repurchase up to $8.0 million of our ordinary shares, par value NIS 0.25 per share, subject to receipt of Israeli court approval. In July 2022, we announced that we had received approval from an Israeli court for the share repurchase program, valid through January 20, 2023.

On December 19, 2022, our board of directors approved the extension of our on-going share repurchase program, with such extension to be in the aggregate amount of up to $5.8 million. The extension was approved by an Israeli court on February 9, 2023, and will expire on the earlier of August 9, 2023, or reaching the additional $5.8 million of repurchases of our ordinary shares.

Under the program, share repurchases may be made from time to time using a variety of methods, including open market transactions or in privately negotiated transactions. Such repurchases will be made in accordance with all applicable securities laws and regulations, including restrictions relating to volume, price and timing under applicable law, including Rule 10b-18 under the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”). The timing and amount of shares repurchased will be determined by our management, within guidelines to be established by the Board or a committee thereof, based on its ongoing evaluation of our capital needs, market conditions, the trading price of our ordinary shares, trading volume and other factors, subject to applicable law. For all or a portion of the authorized repurchase amount, we may enter into a plan compliant with Rule 10b5-1 under the Exchange Act that is designed to facilitate these repurchases.

The repurchase program does not require us to acquire a specific number of shares, and may be suspended or discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases in the future, and any such share repurchases will be funded from available working capital.

As of March 31, 2023, we have repurchased approximately 3.7 million of our ordinary shares at an aggregate amount of $3.3 million under the repurchase program.

~~Cash Flows for the Six Months Ended June 30, 2022 and June 30, 2021 (in thousands):~~

Six Months Ended
June 30,

2022

2021

Net cash used in operating activities

$
(9,377
)

$
(6,340
)
Net cash used in investing activities

(18
)

(11
)
Net cash provided by financing activities

-

50,236

Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash

(164
)

-

Net cash flow

$
(9,559
)

$
(43,885
)

3531

Cash Flows for the Three Months Ended March 31, 2023 and March 31, 2022 (in thousands):

	Three Months Ended March 31,
	2023			2022
Net cash used in operating activities	$	(5,233	)	$	(5,708	)
Net cash used in investing activities		—			(3	)
Net cash used in financing activities		(771	)		—
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash		(11	)		—
Net cash flow	$	(6,015	)	$	(5,711	)

Net Cash Used in Operating Activities

Net cash used in operating activities ~~increased~~decreased by ~~$3.04~~$475 million or ~~48%~~8% primarily due ~~higher consulting and professional services expenses.~~to decreased insurance prepaid expenses, decreased inventory purchases.

Net Cash Provided by Financing Activities

Net cash ~~provided by~~used in financing activities ~~decreased by $50.2 million~~was $771 for the ~~six~~three months ended ~~June 30, 2022~~March 31, 2023 compared to $0 for the ~~six~~three months ended ~~June 30, 2021, primarily~~March 31, 2022. The increase is due to the ~~proceeds received through~~repurchase program of our ~~February 2021 Offering and warrants exercises received during the first quarter of 2021.~~ordinary shares.

Obligations and Contractual Commitments

Set forth below is a summary of our contractual obligations as of ~~June 30, 2022.~~March 31, 2023.

	Payments due by period (in thousands)						Payments due by period (in dollars, in thousands)
Contractual obligations	Total		Less than 1 year		1-3 years		Total		Less than 1 year		1-3 years

Purchase obligations (1)	$	1,147	$	1,147	$	-	$	2,064	$	2,064	$	—
Collaboration Agreement and License Agreement obligations (2)		75		75		-		65		65		—
Operating lease obligations (3)		902		656		246		1,437		662		775
Total	$	2,124	$	1,878	$	246	$	3,566	$	2,791	$	775

(1)	The Company depends on one contract manufacturer, Sanmina Corporation, for both the ReStore products and the SCI Products. We place our manufacturing orders with Sanmina pursuant to purchase orders or by providing forecasts for future requirements.

(2)

~~Our~~ Collaboration Agreement with Harvard was originally for a term of five years, commencing in May 2016, and was subsequently amended in April 2018 to extend the term by one additional year. The Collaboration Agreement expired as of March 31, 2022. Under the Collaboration Agreement, we were required to pay in quarterly installments the funding of our joint research collaboration with Harvard, subject to a minimum funding commitment under applicable circumstances. Our License Agreement with Harvard consists of patent reimbursement expenses payments and a license upfront fee payment. There are also several milestone payments contingent upon the achievement of certain product development and commercialization milestones and royalty payments on net sales from certain patents licensed to Harvard. All product development milestones contemplated by the License Agreement have been met as of ~~June 30, 2022;~~March 31, 2023; however, there are still outstanding commercialization milestones under the License Agreement that depend on us reaching certain sales amounts, some or all of which may not occur. Our Collaboration Agreement with Harvard was concluded on March 31, 2022.

(3)	Our operating leases consist of leases for our facilities in the United States and Israel and motor vehicles.

We calculated the payments due under our operating lease obligation for our Israeli office that are to be paid in NIS at a rate of exchange of NIS ~~3.50:$1.00,~~3.615: $1.00, and the payments due under our operating lease obligation for our German subsidiary that are to be paid in euros at a rate of exchange of ~~1.04 euro:$1:00,~~€1.00: $1.088, both of which were the applicable exchange rates as of ~~June 30, 2022.~~March 31, 2023.

Off-Balance Sheet Arrangements

We had no off-balance sheet arrangements or guarantees of third-party obligations as of ~~June 30, 2022.~~March 31, 2023.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes to our market risk during the ~~second~~first quarter of ~~2022.~~2023. For a discussion of our exposure to market risk, please see Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of our ~~2021~~2022 Form 10-K.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosure.

As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon, and as of the date of, this evaluation, the Chief Executive Officer and the Principal Financial Officer concluded that our disclosure controls and procedures were effective such that the information required to be disclosed by us in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the quarter ended ~~June 30, 2022,~~March 31, 2023 there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

3733

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There have been no material changes to our legal proceedings as described in “Part I, Item 3. Legal Proceedings” of our ~~2021~~2022 Form 10-K, except as described in Note 5 in our condensed consolidated financial statements included in “Part I, Item 1” of this quarterly report.

ITEM 1A. RISK FACTORS

There have been no material changes to our risk factors from those disclosed in “Part I, Item 1A. Risk Factors” of our ~~2021~~2022 Form 10-K except as ~~disclosed in our Quarterly Report on Form10-Q for the three months ended March 31, 2022.~~noted below:

Risks Related to Our Business and Our Industry

We do not satisfy all listing requirements for the Nasdaq Capital Market. We can provide no assurance that we will be able to comply with the continued listing requirements over time and that our common stock will continue to be listed on the Nasdaq Capital Market.

As previously disclosed, on October 10, 2022, we received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company did not satisfy the requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a) (“Rule 5550(a)”) to maintain a minimum bid price of $1 per sharefor the 30 consecutive business days prior to such date. On April 11, 2023, we received a second notification letter from Nasdaq indicating that we have been provided with an additional period of 180 calendar days, or until October 9, 2023, to regain compliance with Rule 5550(a)(2). If at any time before October 9, 2023, the bid price of our ordinary shares closes at $1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation that we have regained compliance. We intend to monitor closely the closing bid price of our ordinary shares and to consider plans for regaining compliance with Rule 5550(a). While we plan to review all available options, there can be no assurance that we will be able to regain compliance with the applicable rules during the second 180-day compliance period, or at all. As in the past, the Nasdaq notification letters are notices of deficiency, not delisting, and do not currently affect the listing or trading of ReWalk ordinary shares on The Nasdaq Capital Market.

If we do not regain compliance with Rule 5550(a) during the applicable cure period, Nasdaq will notify us that our ordinary shares are subject to delisting. We would then be permitted to appeal any delisting determination to a Nasdaq Hearings Panel, and our ordinary shares would remain listed on the Nasdaq Capital Market pending the panel's decision after the hearing. If we do not appeal the delisting determination or do not succeed in such an appeal, our ordinary shares would be removed from trading on the Nasdaq Capital Market. Any delisting determination could seriously decrease or eliminate the value of an investment in our ordinary shares and other securities linked to our ordinary shares. While an alternative listing on an over-the-counter exchange could maintain some degree of a market in our ordinary shares, we could face substantial material adverse consequences, including, but not limited to, the following: limited availability for market quotations for our ordinary shares; reduced liquidity with respect to our ordinary shares; a determination that our ordinary shares are “penny stock” under SEC rules, subjecting brokers trading our ordinary shares to more stringent rules on disclosure and the class of investors to which the broker may sell the ordinary shares; limited news and analyst coverage, in part due to the “penny stock” rules; decreased ability to issue additional securities or obtain additional financing in the future; and potential breaches under or terminations of our agreements with current or prospective large shareholders, strategic investors and banks. The perception among investors that we are at heightened risk of delisting could also negatively affect the market price of our securities and trading volume of our ordinary shares. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement, or prevent future non-compliance with Nasdaq’s listing requirements.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~There~~Items 2(a) and 2(b) are ~~no transactions that have~~ not ~~been previously included in a Current Report on Form 8-K.~~applicable.

Issuer Purchases of Equity Securities

The following table sets forth information regarding the ordinary shares repurchased under our share repurchase program during the three months ended March 31, 2023:

Period	Total Number of Shares Purchased		Average Price Paid Per Share		Total Number of Shares Purchased as Part of a Publicly Announced Plan		(In Thousands) Maximum Value of Shares That May Yet Be Purchased Under the Plan
January 1 - January 31, 2023
Share repurchase program (1)		730,350	$	0.84		730,350	$	4,730

February 1 - February 28, 2023
Share repurchase program (1)		—	$	—		—	$	4,730

March 1 - March 31, 2023
Share repurchase program (1)		—	$	—		—	$	4,730
Quarter Total

Share repurchase program (1)		730,350	$	0.84		730,350	$	4,730

(1) Ordinary Shares were repurchased by us through our publicly announced share repurchase program approved by our Board of Directors on June 2, 2022, and approved by an Israeli court on July 20, 2022. The program was scheduled to expire on the earlier of January 20, 2023, or reaching $8.0 million of repurchases. On December 22, 2022, our Board of Directors approved an extension of the repurchase program, with such extension to be in the aggregate amount of up to $5.8 million. The extension was approved by an Israeli court on February 9, 2023, and will expire on the earlier of August 9, 2023, or reaching the additional $5.8 million of repurchases of our ordinary shares.

Repurchases may take place in open market transactions or in privately negotiated transactions and may be made from time to time depending on market conditions, share price, trading volume and other factors our board of directors deems appropriate. Our board of directors may also suspend and/or discontinue the repurchase program at any time, in its sole discretion. All repurchases will be made in accordance with all applicable securities laws and regulations.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

3835

ITEM 6. EXHIBIT INDEX

Exhibit Number		Description
31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002.
31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act 2002.
32.1		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

__________________________

*	Furnished herewith.

^	Portions of this exhibit (indicated by asterisks) have been omitted under rules of the SEC permitting the confidential treatment of select information.

3936

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ReWalk Robotics Ltd.

Date: ~~August 9, 2022~~May 11, 2023	By:	/s/ Larry Jasinski
		Larry Jasinski
		Chief Executive Officer
		(Principal Executive Officer)

Date: ~~August 9, 2022~~May 11, 2023	By:	/s/ ~~Almog Adar~~Michael Lawless
		~~Almog Adar~~Michael Lawless
		~~Director of Finance and~~Chief Financial Officer
		~~Corporate Financial Controller~~
		(Principal Financial ~~and~~ ~~Principal~~ ~~Accounting~~ Officer)

4037

	US Dollars in thousands
Balance at December 31, 2022	$	92
Provision		87
Usage		(90	)
Balance at March 31, 2023	$	89

	US Dollars in thousands
Balance at December 31, 2021	$	112
Provision		162
Usage		(169	)
Balance at June 30, 2022	$	105

	Number			Average exercise price		Average remaining contractual life (in years)		Aggregate intrinsic value (in thousands)
Options outstanding as of December 31, 2021		61,832		$	38.34		4.55	$	-
Granted		-			-		-		-
Exercised		-			-		-		-
Forfeited		(17,838	)		31.13		-		-
Options outstanding as of June 30, 2022		43,994		$	41.27		4.89	$	-

Options exercisable as of June 30, 2022		41,638		$	43.28		4.79	$	-

	Number			Average exercise price		Average remaining contractual life (in years)		Aggregate intrinsic value (in thousands)
Options outstanding as of December 31, 2022		43,994		$	41.27		4.39	$	-
Granted		-			-		-		-
Exercised		-			-		-		-
Forfeited		(32	)		32.93		-		-
Options outstanding as of March 31, 2023		43,962		$	41.27		4.13	$	-

Options exercisable as of March 31, 2023		43,962		$	41.27		4.13	$	-

	Number of shares underlying outstanding RSUs			Weighted average grant date fair value
Unvested RSUs as of January 1, 2022		1,356,284		$	1.61
Granted		97,735			1.14
Vested		(198,145	)		1.99
Forfeited		(210,641	)		1.53
Unvested RSUs as of June 30, 2022		1,045,233		$	1.51

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Units placed	$	1,457	$	1,313	$	2,235	$	2,455
Spare parts and warranties		113		123		211		297
Total Revenues	$	1,570	$	1,436	$	2,446	$	2,752

	Number of shares underlying outstanding RSUs			Weighted average grant date fair value
Unvested RSUs as of December 31, 2022		2,755,057		$	1.16
Granted		5,000			0.80
Vested		(122,056	)		1.05
Forfeited		(89,063	)		1.19
Unvested RSUs as of March 31, 2023		2,548,938		$	1.16

Range of exercise price	Options and RSUs outstanding as of June 30, 2022		Weighted average remaining contractual life (years) (1)		Options outstanding and exercisable as of June 30, 2022		Weighted average remaining contractual life (years) (1)
RSUs only		1,045,233		-		-		-
$5.37		12,425		6.75		10,095		6.75
$20.42 - $33.75		13,317		5.71		13,291		5.71
$37.14 - $38.75		8,946		1.48		8,946		1.48
$50 - $52.5		6,731		4.97		6,731		4.97
$182.5 - $524.25		2,575		3.35		2,575		3.35
		1,089,227		4.89		41,638		4.79

Range of exercise price	Options and RSUs outstanding as of March 31, 2023	Weighted average remaining contractual life (years) (1)	Options outstanding and exercisable as of March 31, 2023	Weighted average remaining contractual life (years) (1)
RSUs only	2,548,938	-	-	-
$5.37	12,425	5.99	12,425	5.99
$20.42 - $33.75	13,285	4.98	13,285	4.98
$37.14 - $38.75	8,946	0.66	8,946	0.66
$50 - $52.50	6,731	4.22	6,731	4.22
$182.5 - $524	2,575	2.60	2,575	2.60
	2,592,900	4.13	43,962	4.13


(1)	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

Issuance date	Warrants outstanding		Exercise price per warrant		Warrants outstanding and exercisable		Contractual term
	(number)				(number)
December 31, 2015 (1)		4,771	$	7.500		4,771		See footnote (1)
December 28, 2016 (2)		1,908	$	7.500		1,908		See footnote (1)
November 20, 2018 (3)		126,839	$	7.500		126,839		November 20, 2023
November 20, 2018 (4)		106,680	$	9.375		106,680		November 15, 2023
February 25, 2019 (5)		45,600	$	7.187		45,600		February 21, 2024
April 5, 2019 (6)		408,457	$	5.140		408,457		October 7, 2024
April 5, 2019 (7)		49,015	$	6.503		49,015		April 3, 2024
June 5, 2019, and June 6, 2019 (8)		1,464,665	$	7.500		1,464,665		June 5, 2024
June 5, 2019 (9)		87,880	$	9.375		87,880		June 5, 2024
June 12, 2019 (10)		416,667	$	6.000		416,667		December 12, 2024
June 10, 2019 (11)		50,000	$	7.500		50,000		June 10, 2024
February 10, 2020 (12)		28,400	$	1.250		28,400		February 10, 2025
February 10, 2020 (13)		105,840	$	1.563		105,840		February 10, 2025
July 6, 2020 (14)		448,698	$	1.760		448,698		January 2, 2026
July 6, 2020 (15)		296,297	$	2.278		296,297		January 2, 2026
December 8, 2020 (16)		586,760	$	1.340		586,760		June 8, 2026
December 8, 2020 (17)		108,806	$	1.792		108,806		June 8, 2026
February 26, 2021 (18)		5,460,751	$	3.600		5,460,751		August 26, 2026
February 26, 2021 (19)		655,290	$	4.578		655,290		August 26, 2026
September 29, 2021 (20)		8,006,759	$	2.000		8,006,759		March 29, 2027
September 29, 2021 (21)		960,811	$	2.544		960,811		September 27, 2026
		19,420,894				19,420,894

	Three Months Ended June 30,					Six Months Ended June 30,
	2022		2021			2022		2021
Foreign currency transactions and other	$	39	$	(14	)	$	54	$	(28	)
Bank commissions		5		5			14		15
	$	44	$	(9	)	$	68	$	(13	)

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenues based on customer’s location:
United States	$	578	$	654	$	798	$	1,130
Europe		888		726		1,535		1,563
Asia-Pacific		103		55		111		57
Africa		1		1		2		2
Total revenues	$	1,570	$	1,436	$	2,446	$	2,752